Abstracts Archive - Page 2332 of 2607 - ACR Meeting Abstracts

Abstract Number: 1510 • 2013 ACR/ARHP Annual Meeting
Disease Activity In Male Smokers Has A >10-Fold Amplified Effect On Radiographic Damage In Comparison With Female NON-Smokers In Ankylosing Spondylitis
Sofia Ramiro^1,2, A.M. van Tubergen³, Robert Landewé⁴, Carmen Stolwijk⁵, Maxime Dougados⁶, Filip Van den Bosch⁷ and Désirée van der Heijde⁸, ¹Clinical Immunology & Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ²Rheumatology, Hospital Garcia de Orta, Almada, Portugal, ³Department of Internal Medicine, Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ⁴Academic Medical Center Amsterdam & Atrium Medical Center, Heerlen, Netherlands, ⁵Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ⁶Rheumatology B Department, Paris-Descartes University, Cochin Hospital, Paris, France, ⁷Ghent University Hospital, Ghent, Belgium, ⁸Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: We have shown that disease activity has an effect on radiographic progression over the long-term and that gender and symptom duration are effect modifiers.…
Abstract Number: 1511 • 2013 ACR/ARHP Annual Meeting
What Impairs Balance In Ankylosing Spondylitis? Posture Or Disease Activity?
Osman Hakan Gunduz¹, Emel Ece Ozcan¹, Esra Giray¹ and Ilker Yagci², ¹Physical Medicine and Rehabilitation, Marmara University School of Medicine, Istanbul, Turkey, ²Department of Physical Medicine and Rehabilitation, Marmara University School of Medicine, Istanbul, Turkey
Background/Purpose: To compare ankylosing spondylitis (AS) patients and healthy individuals in terms of posture and balance and to identify the factors affecting balance among patients…
Abstract Number: 1512 • 2013 ACR/ARHP Annual Meeting
Smoking and Its Relationship With Clinical, Radiological and Functional Status In Patients With Ankylosing Spondylitis
Fernando Andres Sommerfleck¹, Emilce Edith Schneeberger¹, Natalia Zamora¹, Luis Alejandro Cayetti² and Gustavo Citera¹, ¹Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ²Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina
Background/Purpose: In recent years, smoking has been reported as an environmental risk factor that influence the course of certain diseases such as psoriasis, ulcerative colitis…
Abstract Number: 1514 • 2013 ACR/ARHP Annual Meeting
Drug Survival In Patients Receiving Golimumab Treatment 2010-2013. Results From The Swedish Rheumatology Quality Register
Saedis Saevarsdottir¹, Michele Santacatterina², Leszek Stawiarz³, Carl Turesson⁴, Helena Forsblad⁵, Lennart T.H. Jacobsson⁶ and Staffan Lindblad⁷, ¹Rheumatology Unit, Dept. of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, ²Biostatistics Core Facility, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ³Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden, ⁴Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ⁵Dept of Rheumatology & Inflammation Research, Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ⁶Department of Rheumatology and Inflammation Research, Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ⁷Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Golimumab is a TNF inhibiting biological drug that was approved in Sweden in 2010 for the treatment of Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA)…
Abstract Number: 1515 • 2013 ACR/ARHP Annual Meeting
Influence Of Taking Structural Lesions Into Account In Addition To Inflammatory Lesions On MRI Of The Sacroiliac Joints On The Classification Of Patients With Possible Axial Spondyloarthritis
Rosaline van den Berg¹, Manouk de Hooge¹, Floris van Gaalen¹, Victoria Navarro-Compán¹, Monique Reijnierse², Karen Fagerli³, Robert Landewé^4,5, Maikel van Oosterhout⁶, Roberta Ramonda⁷, Tom Huizinga¹ and Désirée van der Heijde¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Radiology, Leiden University Medical Center, Leiden, Netherlands, ³Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ⁵Rheumatology, Atrium Medical Center, Heerlen, Netherlands, ⁶Rheumatology, GHZ Hospital, Gouda, Netherlands, ⁷Rheumatology Unit, University of Padova, Padova, Italy
Background/Purpose: The ASAS definition of a positive MRI of the sacroiliac joints (MRI-SI+) for the classification of axial spondyloarthritis (axSpA) patients includes inflammatory lesions only1,2.…
Abstract Number: 1516 • 2013 ACR/ARHP Annual Meeting
Safety and Efficacy Of Etanercept In Early Non-Radiographic Axial Spondyloarthritis: A Randomized, Double-Blind, Placebo-Controlled Trial At 24 Weeks
Maxime Dougados¹, Désirée van der Heijde², Joachim Sieper³, Jürgen Braun⁴, Walter P. Maksymowych⁵, Gustavo Citera⁶, James Cheng-Chung Wei⁷, Jan Lenaerts⁸, Ronald Pedersen⁹, Randi Bonin¹⁰, Ehab Y. Mahgoub¹⁰, Bonnie Vlahos¹⁰ and Jack Bukowski¹¹, ¹Rheumatology B Department, Paris-Descartes University, Cochin Hospital, Paris, France, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Charité Universitätsmedizin Berlin, Berlin, Germany, ⁴Rheumazentrum Ruhrgebiet, Herne, Germany, ⁵Medicine, University of Alberta, Edmonton, AB, Canada, ⁶Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁷Institute of Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan, ⁸Reuma Instituut, Hasselt, Belgium, ⁹Specialty Care, Pfizer Inc, Collegeville, PA, ¹⁰Pfizer Inc, Collegeville, PA, ¹¹Department of Specialty Care, Pfizer Inc, Collegeville, PA
Background/Purpose: Limited data are available on the efficacy of anti-TNF agents in non-radiographic axial spondyloarthritis (nr-axSpA). The objective of this analysis is to compare the…
Abstract Number: 1517 • 2013 ACR/ARHP Annual Meeting
Different Imaging Abnormalities Suggestive Of Spondyloarthritis Are Present In Early Axial Spondyloarthritis. Data From The DESIR Cohort
Anna Moltó¹, Simon Paternotte², Désirée van der Heijde³, Pascal Claudepierre⁴, Martin Rudwaleit⁵ and Maxime Dougados⁶, ¹Cochin Hospital, Paris- Descartes University, Paris, France, ²Rheumatology Department, Paris- Descartes University, Cochin hospital, Paris, France, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Rheumatology, Paris-Est University; LIC EA4393; APHP, Henri Mondor Hospital, Creteil, France, ⁵Endokrinologikum, Berlin, Germany, ⁶Université Paris René Descartes and Hôpital Cochin, Paris, France
Background/Purpose: Patients can fulfil the ASAS (Assessment of SpondyloArthritiS) sets of criteria with either objective evidence of sacroiliac joint damage (X-Ray) or inflammation (MRI) (“imaging”…
Abstract Number: 1518 • 2013 ACR/ARHP Annual Meeting
Prevalence Of Spondylarthritis In Individuals Needing To Purchase An Orthopedic Mattress Because Of Chronic Back Pain
Ahmet Eftal Yucel¹, Muzeyyen Temel², Muhtesem Agildere³ and Mustafa Agah Tekindal⁴, ¹Internal Medicine-Rheumatology, Baskent University Faculty of Medicine, Ankara, Turkey, ²Internal Medicine, Baskent University Faculty of Medicine, Ankara, Turkey, ³Radiology, Baskent University Faculty of Medicine, Ankara, Turkey, ⁴Biostatistics, Baskent University Faculty of Medicine, Ankara, Turkey
Background/Purpose: We hypothesize that the real prevalence of spondylarthritis (SpA) is much higher than reported in the literature. In this study, we aimed to investigate…
Abstract Number: 1519 • 2013 ACR/ARHP Annual Meeting
Meeting The ACR 2010 Fibromyalgia Criteria Worsens Disease Activity and Quality Of Life In Patients With Axial Spondyloarthritis Treated With Infliximab
Mathieu Verdet¹, Clément Guillou², Julien Michaud¹, Christopher Banse¹, Sandra Desouches¹, Gilles Avenel³, Quentin Bréhier⁴, Aurélia Bisson-Vaivre¹, Sophie Pouplin¹ and Olivier Vittecoq⁵, ¹Rheumatology, Rouen University Hospital, Rouen, France, ²Inserm 905 & Institute for Biomedical Research, University of Rouen, Rouen, France, ³Rheumaotlogy, Rouen University Hospital, Rouen, France, ⁴Rheumatology, Le Havre Hospital, Le Havre, France, ⁵Rheumatology, Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France
Background/Purpose: Managing axial spondyloarthritis (aSpA) may be difficult because sometimes patients are not good responder to anti-TNF. We made the hypothesis that in certain patients,…
Abstract Number: 1520 • 2013 ACR/ARHP Annual Meeting
Reduction Of Disease Burden On Workplace and Household Productivity In Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis, Over 48 Weeks Of Treatment With Certolizumab Pegol
Désirée M. van der Heijde¹, Jürgen Braun², Martin Rudwaleit³, Oana Purcaru⁴ and Arthur Kavanaugh⁵, ¹Dept of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumazentrum Ruhrgebiet, Herne, Germany, ³Endokrinologikum, Berlin, Germany, ⁴UCB Pharma, Brussels, Belgium, ⁵Division of Rheumatology Allergy and Immunology, University of California San Diego, San Diego, CA
Background/Purpose: Axial spondyloarthritis (axSpA) includes both ankylosing spondylitis (AS, meeting modified New York criteria) and axSpA with no sacroiliitis on X-ray (non-radiographic axSpA, nr-axSpA). AS…
Abstract Number: 1492 • 2013 ACR/ARHP Annual Meeting
Histone Deacetylase 1 But Not 2 Is Highly Expressed In The Lymphocyte Foci In The Labial Glands Of Patients With Sjogren’s Syndrome
Juan Guo and Wei Zhou, Department of Rheumatology and Immunology, Peking University First Hospital, Beijing, China
Background/Purpose: Sjogren’s syndrome (SS) is an autoimmune disease with abnormally infiltrating lymphocytes in exocrine glands expressing Th1 cytokines and increased incidence of lymphoma. Histone deacetylases…
Abstract Number: 1478 • 2013 ACR/ARHP Annual Meeting
The Prevalence Of Biological Monotherapy Among Rheumatoid Arthritis Patients In Denmark: Results From The Danish Nationwide Danbio Registry
Tanja Schjoedt Joergensen¹, Lars-Erik Kristensen², Tove Lorenzen³, Jørgen Jensen⁴, Lida Zanjani⁵, Toke Laursen⁶, Sheraz Butt⁷, Mette Y. Dam⁸, Hanne M. Lindegaard⁹, Jakob Espesen¹⁰, Oliver Hendricks¹¹, Prabhat Kumar¹², Anita Kincses¹³, Line H. Larsen¹⁴, Marlene Andersen¹⁵, Esben K. Næser¹⁶, Dorte V. Jensen¹⁷, Jolanta Grydehøj¹⁸, Barbara Unger¹⁹, Ninna Dufour²⁰, Vibeke N. Sørensen²¹, Sara Vildhøj²², Inger Marie J. Hansen²³, Johnny Raun²⁴ and Merete Lund Hetland²⁵, ¹The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen F, Denmark, ²Dept of Clinical Sciences, Lund, Section for Rheumatology, Lund University, Faculty of Medicine, Malmö, Sweden, ³Department of Rheumatology, Region Hospital Silkeborg, Silkeborg, Denmark, ⁴Department of Rheumatology, Køge, Denmark, ⁵Department of Rheumatology, Glostrup, Denmark, ⁶Department of Rheumatology, Gentofte, Denmark, ⁷Department of Rheumatology, Frederiksberg, Denmark, ⁸Department of Rheumatology, Aarhus, Denmark, ⁹Department of Rheumatology, Odense University Hospital, Odense, Denmark, ¹⁰Department of Rheumatology, Vejle, Denmark, ¹¹Department of Rheumatology, Gråsten, Denmark, ¹²Department of Rheumatology, Esbjerg, Denmark, ¹³Department of Rheumatology, Copenhagen, Denmark, ¹⁴Department of Rheumatology, Aalborg, Denmark, ¹⁵Department of Rheumatology, Aalborg University, Hjørring, Denmark, ¹⁶Department of Rheumatology, Silkeborg, Denmark, ¹⁷Department of Rheumatology, Rønne, Denmark, ¹⁸Department of Rheumatology, Viborg, Denmark, ¹⁹Department of Rheumatology, Horsens, Denmark, ²⁰Department of Rheumatology, Helsingør, Denmark, ²¹Department of Rheumatology, Randers, Denmark, ²²Department of Rheumatology, Holstebro, Denmark, ²³Department of Rheumatology, Svendborg, Denmark, ²⁴Department of Rheumatology, Fredericia, Denmark, ²⁵Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, The Danish Rheumatologic Database (DANBIO), Glostrup Hospital., Copenhagen, Denmark
Background/Purpose: It is estimated that between 10 and 30% of rheumatoid arthritis (RA) patients are methotrexate (MTX)-intolerant and discontinuation is common in clinical practice. For…
Abstract Number: 1480 • 2013 ACR/ARHP Annual Meeting
Prevalance Of Rare Variants In Methotrexate Pathway Genes: Implications From The National Heart Lung Blood Institute (NHLBI) Exome Sequencing Project
Fardina Malik, Internal Medicine, Alton Memorial Hospital, Alton, IL
Background/Purpose: Inter-individual variation to methotrexate (MTX) therapy in patients with rheumatoid arthritis (RA) is attributed at least in part to the presence of genetic variation…
Abstract Number: 1479 • 2013 ACR/ARHP Annual Meeting
Relationship Between physicians’ Decision To Use Concomitant Glucocorticoid and Remission During Treatment With Tocilizumab In Patients With Background Of Limited Dose Of MTX
Toshihisa Kojima¹, Nobunori Takahashi², Koji Funahashi³, Shuji Asai¹, Masahiro Hanabayashi¹, Shinya Hirabara⁴, Nobuyuki Asai⁵ and Naoki Ishiguro², ¹Orthopedic Surgery and Rheumatology, Nagoya University Hospital, Nagoya, Japan, ²Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ³Orthopedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ⁴Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Japan, ⁵Nagoya Univeristy Hospital, Nagoya, Japan
Background/Purpose: Now, predictive factors at baseline for the good outcome of treatment with biologics are very important not to waste time to treatment goal “remission”.…
Abstract Number: 1481 • 2013 ACR/ARHP Annual Meeting
Negative Effect Of Glucocorticoids Persistence Therapy On Porosity In Rheumatoid Arthritis Patients Treated With TNFα Blockers
Hubert Marotte¹, Sara Djemouai², Béatrice Pallot-Prades², Hervé Locrelle³ and Thierry Thomas⁴, ¹LBTO INSERM U1059 University Jean Monnet, Saint-Etienne, France, ²University Hospital, Saint-Etienne, France, ³INSERM U1059 and University Hospital, Hôpital Nord, Saint-Etienne, France, ⁴INSERM U1059 and University Hospital, Saint-Etienne, France
Background/Purpose: Rheumatoid arthritis is the most common joint inflammatory disease associated with an increased risk of bone fractures. The standard of therapeutic strategy is to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].